Compare · JNJ vs TRAX
JNJ vs TRAX
Side-by-side comparison of Johnson & Johnson (JNJ) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $598.96B, about 465.6x TRAX ($1.29B).
- Over the past year, JNJ is up 51.9% and TRAX is up 107.3% - TRAX leads by 55.4 points.
- JNJ has hit the wire 9 times in the past 4 weeks while TRAX has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 8 for TRAX).
- Company
- Johnson & Johnson
- First Tracks Biotherapeutics Inc.
- Price
- $249.65+0.32%
- $38.38+3.90%
- Market cap
- $598.96B
- $1.29B
- 1M return
- +9.39%
- +121.06%
- 1Y return
- +51.94%
- +107.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 8
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Latest TRAX
- First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Director Schmid John P. converted options into 6,030 shares, increasing direct ownership by 19% to 37,652 units (SEC Form 4)
- Director Marquet Magda converted options into 6,030 shares, increasing direct ownership by 61% to 15,960 units (SEC Form 4)
- Director Jain Rita converted options into 7,330 shares, increasing direct ownership by 62% to 19,194 units (SEC Form 4)
- Director Orwin John A converted options into 6,030 shares, increasing direct ownership by 57% to 16,695 units (SEC Form 4)
- Director Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 63% to 15,660 units (SEC Form 4)
- Director Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 121% to 10,995 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Fenton Dennis M
- Amendment: SEC Form 4 filed by Director Jain Rita
- Amendment: SEC Form 4 filed by Director Marquet Magda